mTOR pathway inhibition in renal cell carcinoma
Authors:
- Alvaro Pinto MarínAMAlvaro Pinto Marín
- Andrés Redondo SánchezASAndrés Redondo Sánchez
- Enrique Espinosa ArranzEAEnrique Espinosa Arranz
- Pilar Zamora AuñónPAPilar Zamora Auñón
- Beatriz Castelo FernándezBFBeatriz Castelo Fernández
- Manuel González BarónMBManuel González Barón
- 1 July 2012
- journal article
- review article
- Published by Elsevier in Urologic Oncology: Seminars and Original Investigations
- Vol. 30 (4) , 356-361
Abstract
No abstract availableKeywords
This publication has 35 references indexed in Scilit:
- Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trialThe Lancet, 2008
- Mechanisms of Disease: survival benefit of temsirolimus validates a role for mTOR in the management of advanced RCCNature Clinical Practice Oncology, 2008
- Dose- and Schedule-Dependent Inhibition of the Mammalian Target of Rapamycin Pathway With Everolimus: A Phase I Tumor Pharmacodynamic Study in Patients With Advanced Solid TumorsJournal of Clinical Oncology, 2008
- Phase I Pharmacokinetic and Pharmacodynamic Study of the Oral Mammalian Target of Rapamycin Inhibitor Everolimus in Patients With Advanced Solid TumorsJournal of Clinical Oncology, 2008
- Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trialThe Lancet, 2007
- Sorafenib in Advanced Clear-Cell Renal-Cell CarcinomaNew England Journal of Medicine, 2007
- The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolismNature Reviews Genetics, 2006
- Phosphorylation and Regulation of Akt/PKB by the Rictor-mTOR ComplexScience, 2005
- Dysregulation of the TSC-mTOR pathway in human diseaseNature Genetics, 2004
- A mammalian protein targeted by G1-arresting rapamycin–receptor complexNature, 1994